ROCKVILLE, MD and SHENZHEN, CHINA, June 21, 2024 – (ACN Newswire) – HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multi-targeted therapies for chronic liver and metabolic diseases, announced today that it will present at the American Diabetes Association’s (ADA) 84th Scientific Sessions…
Read More